• L-Glutathione Reduced: Optimizing Redox and GST Workflows

  2026-06-03

  L-Glutathione Reduced enables high-fidelity redox and GST affinity workflows, delivering reproducible results in oxidative stress and cancer metabolism research. This guide translates the latest mechanistic insights into actionable protocols and troubleshooting strategies, leveraging APExBIO’s trusted reagent for robust, publication-grade data.

• Pazopanib Hydrochloride: Next-Gen Oncology Workflows & Proto

  2026-06-03

  Pazopanib Hydrochloride (GW786034) empowers cancer researchers with multi-target kinase inhibition and reproducible anti-angiogenic effects. This article translates the latest in vitro evaluation strategies and troubleshooting insights into actionable protocols, informed by benchmarked evidence and comparative analyses.

• Staurosporine: Elevating Translational Oncology with Mechani

  2026-06-02

  Staurosporine, a benchmark broad-spectrum serine/threonine protein kinase inhibitor, is reshaping translational cancer research by enabling precise dissection of kinase signaling, apoptosis, and angiogenesis inhibition. This thought-leadership article blends mechanistic understanding with actionable protocol guidance, spotlights APExBIO’s gold-standard Staurosporine, and bridges advanced methodologies such as high-throughput fractional killing quantification. We contextualize new evidence about therapy-induced prometastatic states and provide a strategic roadmap for researchers seeking to translate molecular findings into innovative anti-cancer strategies.

• Cinoxacin in Gram-Negative Infection Models: Protocols & Ins

  2026-06-02

  Cinoxacin, a classic quinolone antibiotic, empowers researchers with precise inhibition of Gram-negative bacteria, making it indispensable for urinary tract infection research and resistance profiling. This guide translates evidence-backed protocols and troubleshooting strategies into actionable workflows, leveraging APExBIO's Cinoxacin for reproducibility and data-driven results.

• LY364947: Reliable TGF-β Type I Receptor Kinase Inhibitor fo

  2026-06-01

  This article examines real laboratory challenges in TGF-β/EMT research and demonstrates how LY364947 (SKU B2287) serves as a reproducible, high-quality solution for cell viability, proliferation, and cytotoxicity studies. Through data-supported scenario analyses, we highlight protocol optimization, assay compatibility, and vendor reliability, establishing LY364947 as a trusted tool for robust experimental outcomes.

• Sodium Picosulfate: Applied Workflows in Gut–Liver–Brain Res

  2026-06-01

  Sodium Picosulfate, supplied by APExBIO, accelerates translational research in gastrointestinal and neuroinflammation models by enabling precise modulation of water and electrolyte dynamics. This article translates cutting-edge evidence into actionable protocols and troubleshooting tactics for chronic constipation and gut–liver–brain axis studies.

• Gut Microbiota Modulates PCN’s Hepatoprotection via YAP in S

  2026-05-31

  This study demonstrates that gut microbiota is essential for the protective effects of the mouse PXR agonist Pregnenolone-16α-carbonitrile (PCN) against sepsis-induced liver injury, acting through YAP pathway activation. The findings highlight a novel gut-liver axis mechanism, informing future research on hepatic detoxification and antifibrotic strategies.

• Cand2 Modulates Ubiquitination and Autophagy in Fungal Patho

  2026-05-30

  This study identifies Cand2 as a key inhibitor of CRL-mediated ubiquitination, regulating autophagy and pathogenicity in the rice blast fungus Magnaporthe oryzae. The work reveals conserved mechanisms linking protein homeostasis to fungal virulence, offering new targets for crop protection strategies.

• CBD Reduces Orofacial Inflammatory Pain via Endocannabinoid

  2026-05-29

  This study demonstrates that cannabidiol (CBD) robustly attenuates both sensory and affective dimensions of orofacial inflammatory pain in mice. By dissecting peripheral and central endocannabinoid signaling, the research provides a translational foundation for novel therapies targeting complex pain syndromes and their emotional comorbidities.

• Balsalazide as a Targeted 5-ASA Prodrug for Ulcerative Colit

  2026-05-29

  The reference study by Wiggins & Rajapakse introduces balsalazide as a novel prodrug formulation for delivering 5-aminosalicylate in the treatment of active ulcerative colitis. The review highlights the drug’s improved efficacy in remission induction and rapidity of onset, alongside a favorable safety profile, compared to other oral 5-ASA agents. These findings have important implications for optimizing anti-inflammatory strategies in gastrointestinal research.

• Phosphatase Inhibitor Cocktail 1: Optimizing Phosphoproteomi

  2026-05-28

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) from APExBIO empowers researchers to preserve phosphorylation states with precision across demanding proteomic and signaling assays. By targeting both alkaline and serine/threonine phosphatases, this cocktail ensures data integrity for Western blotting, co-immunoprecipitation, and advanced phosphoproteomic analysis.

• DiD (DiDC 18 (5)): Precision Plasma Membrane Tracking in Inf

  2026-05-28

  Explore how DiD (DiDC 18 (5)) empowers advanced cell membrane tracking and neuronal tracing with unmatched spectral clarity. This article uniquely analyzes DiD’s mechanistic role in dissecting inflammatory cycles and mitochondrial dysfunction, offering actionable insights for assay optimization.

• Calpain Inhibition Restores Offspring Cognition After Matern

  2026-05-27

  A recent study demonstrates that excessive calpain activity following maternal non-obstetric surgery impairs offspring cognition by disrupting BDNF/TrkB signaling. Pharmacological inhibition of calpain with MDL 28170 postnatally partially restores hippocampal structure and cognitive function, highlighting a mechanistic pathway for neurodevelopmental protection.

• Linoleic Acid–PPARα–TF Axis Drives pLELC Progression: Proteo

  2026-05-27

  This study delineates a mechanistic link between linoleic acid, PPARα activation, and tissue factor (TF) upregulation in primary pulmonary lymphoepithelioma-like carcinoma (pLELC). By integrating proteomics and metabolomics with patient-derived xenograft validation, the research identifies the LA–PPARα–TF axis as a key driver of tumor progression and highlights TF as a potential therapeutic target.

• Machine Learning-Driven Discovery of Novel Senolytics

  2026-05-26

  This study introduces a machine learning approach for identifying new senolytic compounds, leveraging existing heterogeneous data to dramatically reduce screening costs. The findings demonstrate both the potential and current limitations of AI-powered drug discovery in targeting cellular senescence, with practical implications for cancer, aging, and translational research.

16396 records 1/1094 page Next 12345 下5页 Last page